CareDx, Inc. (CDNA)

NASDAQ: CDNA · Real-Time Price · USD

63.67

+1.47 (2.36%)

At close: Oct 9, 2026, 4:00 PM EDT

63.68

+0.01 (0.02%)

After-hours: Oct 9, 2026, 7:45 PM EDT

Market Cap	3.29B +318.4%
Revenue (ttm)	458.09M +34.4%
Net Income	111.01M +90.9%
EPS	2.12 +112.5%
Shares Out	51.73M
PE Ratio	30.03
Forward PE	59.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	897,071
Open	62.21
Previous Close	62.21
Day's Range	62.21 - 65.13
52-Week Range	13.95 - 72.51
Beta	2.38
Analysts	Buy
Price Target	58.83 (-7.6%)
Est. Earnings	Nov 3, 2026

About CDNA

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about dist... [Read more]

Industry Diagnostics & Research

Sector Healthcare

IPO Date Jul 17, 2014

Employees 765

Stock Exchange Nasdaq

Ticker Symbol CDNA

Website https://caredx.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price target is $58.83, which is a decrease of -7.60% from the latest price.

Price Target

$58.83

(-7.60% downside)

Analyst Consensus: Buy

Stock Forecasts

News

CareDx management to meet with Piper Sandler

Meeting to be held in New York on October 2 hosted by Piper Sandler.

9 days ago - TheFly

CareDx rises 9.1%

CareDx (CDNA) is up 9.1%, or $4.92 to $59.23.

15 days ago - TheFly

CareDx price target raised to $74 from $60 at BTIG

BTIG raised the firm’s price target on CareDx (CDNA) to $74 from $60 and keeps a Buy rating on the shares ater hosting investor talks with its management team. CareDx…

16 days ago - TheFly

CareDx management to meet with BTIG

Meeting to be held in Boston on September 22 hosted by BTIG.

4 weeks ago - TheFly

CareDx initiated with a Buy at Canaccord

Canaccord initiated coverage of CareDx (CDNA) with a Buy rating and $65 price target The company’s leadership position in transplant diagnostics “provides a durable competitive advantage,” the analyst...

5 weeks ago - TheFly

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of indu...

2 months ago - Business Wire

CareDx price target raised to $60 from $45 at BTIG

BTIG raised the firm’s price target on CareDx (CDNA) to $60 from $45 and keeps a Buy rating on the shares. CareDx delivered a solid Q2 beat-and-raise, with the Medicare…

2 months ago - TheFly

Craig-Hallum ups CareDx to Buy, says guidance feels conservative

As previously reported, Craig-Hallum analyst Bill Bonello upgraded CareDx (CDNA) to Buy from Hold with a price target of $64, up from $35. With shares up 132% year-to-date, the firm…

2 months ago - TheFly

CareDx upgraded to Buy from Hold at Craig-Hallum

Craig-Hallum upgraded CareDx (CDNA) to Buy from Hold with a price target of $64, up from $35.

2 months ago - TheFly

CareDx Earnings Call Transcript: Q2 2026

Q2 2026 revenue grew 52% to $132M, with strong gains in testing services and successful integration of NavDx. Raised 2026 guidance to $490–$500M revenue and $66–$78M adjusted EBITDA, driven by growth in transplant and specialty oncology. Clinical and reimbursement milestones support continued expansion.

2 months ago - Transcripts